1-3 of 3
protein tyrosine kinase
Close
Sort by
Journal Articles

Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19

Chaja F. Jacobs, Eric Eldering, Arnon P. Kater
Journal: Blood Advances
Blood Adv (2021) 5 (3): 913–925.
https://doi.org/10.1182/bloodadvances.2020003768
Published: 2021
Includes: Supplemental data
Journal Articles

Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD + AML

Silvia Masciarelli, Ernestina Capuano, Tiziana Ottone, Mariadomenica Divona, Serena Lavorgna, Francesca Liccardo, Martyna Śniegocka, Serena Travaglini, Nelida I. Noguera, Alessandra Picardi, Vincenzo Petrozza, Alessandro Fatica, Luca Tamagnone, Maria Teresa Voso, Francesco Lo Coco, Francesco Fazi
Journal: Blood Advances
Blood Adv (2019) 3 (24): 4155–4160.
https://doi.org/10.1182/bloodadvances.2019000540
Published: 2019
Includes: Supplemental data
Journal Articles

Co-occurrence of FLT3 -TKD and NPM1 mutations defines a highly favorable prognostic AML group

Clinical Trials & Observations
Prajwal Boddu, Hagop Kantarjian, Gautam Borthakur, Tapan Kadia, Naval Daver, Sherry Pierce, Michael Andreeff, Farhad Ravandi, Jorge Cortes, Steven M. Kornblau
Journal: Blood Advances
Blood Adv (2017) 1 (19): 1546–1550.
https://doi.org/10.1182/bloodadvances.2017009019
Published: 2017
Includes: Supplemental data